Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies. - Concepedia

Concepedia

Publication | Closed Access

Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.

51

Citations

0

References

2016

Year

Toshinori Sueda, Daisuke Sakai, Toshihiro Kudo, Takashi Sugiura, Hidekazu Takahashi, Naotsugu Haraguchi, Junichi Nishimura, Taishi Hata, Tarō Hayashi, Tsunekazu Mizushima,

Abstract

Our results showed that regorafenib and TAS-102 have comparable efficacy but different toxicity profiles in patients with mCRC. Both are considered new salvage treatment options. Differences in the toxicity profiles between the two treatments will help in choosing regorafenib or TAS-102.